

ECRIN – European Clinical Research Infrastructure Network

Supporting Clinical Trials Across Borders



Serena Battaglia | June 20th, Brussels

Context

Why ECRIN?

- Need for multinational trials
 - Greater access to patients, medical expertise and appropriate facilities
 - Higher methodological standards
 - Shared costs, tools and procedures
 - Potential for broad implementation of research outcomes
 - Avoidance of duplication of trials
- But several obstacles to multinational trials
 - Infrastructure interoperability, regulation, ethical review, insurance, contracts, management, cost models, funding, languages, etc.

Context

Why ECRIN?

- ECRIN as a solution
 - Provides support to sponsors in investigator-initiated trials
 - A pathway through Europe's fragmented health and legal systems
 - development of innovative health products
 - exploration of new indications for authorised health products
 - comparative assessment of efficacy and safety of approved healthcare strategies

Organisation: Distributed Infrastructure

EuCos, Core Team, National Partners

- **European Correspondents (EuCos)**
 - Implement work in-country in coordination with national partners
- **Core Team**
 - Develops ECRIN's strategy, common tools and procedures
 - Supports EuCos
- **National Partners** (networks of clinical trial units, CTUs)
 - Manage trials in-country and provide services to ECRIN
 - Host EuCos



Main Activity: Trial Support

Coordinated Support from Preparation to Implementation

1

PREPARATION



ECRIN GIVES ADVICE AND INFORMATION ON:

- Funding sources and applications
- Investigation sites and patient recruitment
- Clinical trial units (location, services)
- Regulatory, ethical and insurance requirements
- Trial methodology
- Cost of trial management services

2

PROTOCOL REVIEW



ECRIN'S SCIENTIFIC BOARD AND EUROPEAN CORRESPONDENTS PROVIDE:

- Scientific and methodological evaluation of the full protocol
- Logistical assessment of project implementation plans

3

TRIAL MANAGEMENT




ECRIN COORDINATES AND SUPPORTS:

- Submissions to competent authorities and ethics committees
- Monitoring
- Adverse event reporting
- Data management
- Health product and biosample management

ECRIN trial portfolio

average 7 countries per trial (eligibility: projects involving at least 2 ECRIN countries)



Support innovative SMEs in the healthcare biotechnology sector *(Call H2020 dedicated SME instrument)*

- Development of clinical trials for the validation of biomarkers and/or medical devices
 - New EU regulation
- New trial design (adaptive design, basket studies)
 - More flexible, efficient and fast clinical trials
 - Targeted therapies
- Data sharing and re-use services
 - Reproducibility of results
 - Reduce the number of clinical trials


How can ECRIN stimulate innovation in Europe?

- Collaborative approach
 - Overcome challenges and support trials with the greatest public health impact
- Trial design and methodology
 - Reduce the number and the cost of clinical trials
 - Improve the efficacy (faster access to treatments)
- Health policies and clinical guidelines for health professionals
 - Ask “What is the **best treatment option** for this patient/disease?” rather than “Is this particular product effective and safe?”

Thank you!

ECRIN trial portfolio

Disease areas



Calls 2016

